ARTICLE | Clinical News
Inclisiran lowers LDL-C in ORION-11, clearing first Phase III hurdle
August 26, 2019 9:18 PM UTC
Data showing whether Medicines Co.'s inclisiran has more than a dosing advantage over anti-PCSK9 mAbs will come next week as the biotech reported top-line results Monday.
The Medicines Co. (NASDAQ:MDCO) said the siRNA against PCSK9 met the primary and secondary endpoints in the Phase III ORION-11 trial to lower LDL-C levels in 1,617 patients with atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents and elevated LDL-C. ...
BCIQ Target Profiles